Severe Asthma Digital Marketing Trends Report 2022 Featuring Sanofi, Regeneron, Genentech, Novartis, GSK, AstraZeneca, Amgen, & Teva

DUBLIN, Nov. 21, 2022 /PRNewswire/ -- The "Digital Marketing Trends in Severe Asthma" report has been added to ResearchAndMarkets.com's providing.

Sanofi/Regeneron's Dupixent.com achieved the best site visitors throughout branded extreme bronchial asthma affected person websites within the US from July 2021 to June 2022, with about 7,800,000 visits, adopted by Novartis' Xolair.com, and GSK's Nucala.com.

The very best proportion of site visitors to those websites originated from direct sources, adopted by natural searches. Amgen/AstraZeneca's Tezspire.com had the best quantity of direct site visitors (83%), whereas remaining manufacturers, Dupixent, Cinqair, Nucala, and Xolair, had ranges between 52-66%.

For affected person branded websites, Sanofi/Regeneron spent probably the most on DDA for Dupixent.com at roughly $4.2 million, adopted by GSK's Nucala.com at roughly $900,000. Dupixent.com was supported by probably the most paid key phrases at roughly 10,650 key phrases, adopted by Tezspire.com at about 5,800 key phrases.

For branded HCP websites within the US, Sanofi/Regeneron's Dupixenthcp.com had the best variety of visits at roughly 775,000 complete visits, adopted by AstraZeneca's Fasenrahcp.com, and GSK's Nucalahcp.com. The very best proportion of site visitors to those websites originated from direct, adopted by natural and referral sources.

Teva's Cinqairhcp.com had the best proportion of site visitors from direct searches (81%). Sanofi/Regeneron spent probably the most on DDA for Dupixenthcp.com at roughly $51,400, adopted by Amgen/AstraZeneca's Tezspirehcp.com at roughly $17,100.

Between July 2021 and June 2022, the highest 20 social media bronchial asthma posts by interplay from pharma had been from Sanofi's Fb accounts, Genentech's Instagram, Regeneron's Instagram, Fasenra's Fb, and GSK's Instagram. AstraZeneca's Vik Bronchial asthma is the one extreme bronchial asthma app detected from pharma within the US, with an estimated 30,700 downloads in 2021.

Most branded web sites in EUCAN are patient-directed and few generated notable site visitors between July 2021 and June 2022. Sanofi/Regeneron's Dupixentmyway.co.uk and Dupixent.co.uk achieved the best site visitors, with about 20,200 and three,400 visits, respectively.

Between July 2021 and June 2022, eight of the highest 20 social media bronchial asthma posts by interplay in EUCAN from pharma had been from AstraZeneca Espana's Instagram account. No bronchial asthma cell apps had been detected from pharma in EUCAN.

Scope

  • This report assesses key digital advertising and marketing metrics of pharma property in extreme bronchial asthma, together with branded web sites for sufferers and healthcare professionals (HCPs), cell apps, and social media accounts.
  • Metrics embrace web site site visitors quantity, engagement, and supply, digital show promoting (DDA), paid search engine marketing (search engine marketing), cell app downloads, and social media submit interplay.
  • Nations embrace the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).

Causes to Purchase

  • Perceive the digital advertising and marketing aggressive panorama in extreme bronchial asthma, with a view of main affected person and HCP branded property throughout totally different areas.
  • See what ways pharma corporations are utilizing to drive site visitors to their extreme bronchial asthma branded property for affected person and HCPs, resembling DDA and paid search engine marketing.
  • Perceive what sources of web site site visitors are producing probably the most visits to those property, resembling paid search engine marketing, social media, or natural searches.
  • Evaluate prime branded property for sufferers by how they tackle and assist totally different affected person wants.
  • See what pharma social media accounts in extreme bronchial asthma are probably the most lively and reaching probably the most engagement.
  • See main cell app choices in extreme bronchial asthma from pharma throughout totally different areas.

Key Matters Lined:

  • Govt Abstract
  • US Affected person Branded Web sites
  • US HCP Branded Web sites
  • US Digital Show Promoting and Search Engine Optimization
  • US Cellular Apps and Social Media
  • EUCAN Branded Web sites
  • EUCAN Cellular Apps and Social Media
  • Appendix

Corporations Talked about

  • Sanofi
  • Regeneron
  • Genentech
  • Novartis
  • GSK
  • AstraZeneca
  • Amgen
  • Teva

For extra details about this report go to https://www.researchandmarkets.com/r/dzcu6v

Media Contact:
Analysis and Markets
Laura Wooden, Senior Supervisor
[email protected]
 
For E.S.T Workplace Hours Name +1-917-300-0470
For U.S./CAN Toll Free Name +1-800-526-8630
For GMT Workplace Hours Name +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (exterior U.S.): +353-1-481-1716

Brand: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Analysis and Markets



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Seo Global